Form 4: Theravance Biopharma Director Donal O'Connor Reports Share Acquisition and Option Grant

Director Donal O'Connor reports acquisition of shares and grant of share options in Theravance Biopharma.

Summary

• On May 8, 2024, Donal O'Connor, a director of Theravance Biopharma, reported acquiring 10,537 ordinary shares.
• These shares were acquired at a price of $0.
• Following the transaction, O'Connor directly owns 63,555 ordinary shares.
• O'Connor also acquired 23,576 share options with an exercise price of $9.49 on the same date.
• These options vest in installments over time, with full vesting contingent on continued service and the next annual shareholder meeting.
• Following the transaction, O'Connor directly owns 23,576 share options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitively bullish.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from a company director.

Key Dates